Radhika Mishra

This study identifies senescent cancer-associated fibroblasts (senCAFs) driven by MK2 that promote immunosuppression in bone metastases and shows that combining MK2 inhibition with OX40 agonists enhances immunotherapy efficacy.

This study identifies senescent peripheral fibroblasts as the initiators of chemotherapy-induced peripheral neuropathy, showing that targeting MK2 in these cells can prevent and reverse the condition.